title: Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
authors.affiliation: Bone Marrow Transplant Program, Division of Hematology and Oncology, Department of Medicine, LSU Health Sciences Center Shreveport, Shreveport, LA 71103, USA.
authors.forename: Jaime L
authors.initials: JL
authors.lastname: Shahan
authors.forename: Lori D
authors.initials: LD
authors.lastname: Panu
authors.forename: Gerhard C
authors.initials: GC
authors.lastname: Hildebrandt
mesh_terms: D000588:Amines / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003131:Combined Modality Therapy; D052283:Creatine Kinase, MM Form / Q000097:blood; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage; D004357:Drug Synergism; D005260:Female; D000077206:Gabapentin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D007674:Kidney Diseases / Q000139:chemically induced; D000077269:Lenalidomide; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D036102:Peripheral Blood Stem Cell Transplantation; D011115:Polyneuropathies / Q000150:complications / Q000188:drug therapy; D017035:Pravastatin / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011719:Pyrazines / Q000008:administration & dosage; D012206:Rhabdomyolysis / Q000139:chemically induced*; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000588:Amines; D015415:Biomarkers; D001897:Boronic Acids; D003509:Cyclohexanecarboxylic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007155:Immunologic Factors; D011719:Pyrazines; D013792:Thalidomide; D005680:gamma-Aminobutyric Acid; D000069286:Bortezomib; D000077206:Gabapentin; D003907:Dexamethasone; D052283:Creatine Kinase, MM Form; D000077269:Lenalidomide; D017035:Pravastatin; D008558:Melphalan